Sorafenib is currently the standard chemotherapy drug for treatment of advanced
hepatocellular carcinoma (HCC). But its efficacy requires improvement, it is imperative to …

An antimalarial medication, artesunate (Art), has exhibited promising anticancer effects with
excellent tolerability in various types of cancer, suggesting that it has the potential to be used …

Background: Sorafenib is a potent inhibitor against Raf kinase and several receptor tyrosine
kinases that has been approved for the clinical treatment of advanced renal and liver cancer …

Enhancing sensitivity of carcinoma to sorafenib (Sor) is critical to overcome the limits of high
frequency resistance and moderate efficiency during chemotherapy for advanced …

Sorafenib is a small‑molecule multi‑kinase inhibitor approved by FDA as an oral agent for
the treatment of hepatocellular carcinoma (HCC) and renal cell carcinoma. However …

Sorafenib is effective for patients with advanced hepatocellular carcinoma (HCC) and
particularly for those who are unsuitable to receive life-prolonging transarterial …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Sorafenib (SOR) is the first-line treatment for hepatocellular carcinoma (HCC). However, its
use is hindered by the recently expressed safety concerns. One approach for reducing SOR …

Abstract Sorafenib (Nexavar, BAY43‑9006 or Sora) is the first molecular targeted agent that
has exhibited significant therapeutic benefits in advanced hepatocellular carcinoma (HCC) …

Background Sorafenib is the most widely used first-line treatment for patients with advanced
hepatocellular carcinoma (HCC), but such treatment provides only limited survival benefits …